Nuvation Bio
NUVB
116 hedge funds and large institutions have $203M invested in Nuvation Bio in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 43 increasing their positions, 33 reducing their positions, and 23 closing their positions.
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
30% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 33
10% more capital invested
Capital invested by funds: $183M → $203M (+$19.2M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.21% less ownership
Funds ownership: 62.53% → 61.32% (-1.2%)
7% less funds holding
Funds holding: 125 → 116 (-9)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.5M |
| 2 |
Millennium Management
New York
|
+$2.21M |
| 3 |
Renaissance Technologies
New York
|
+$1.41M |
| 4 |
Citigroup
New York
|
+$1.36M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$10.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.43M |
| 3 |
6CM
683 Capital Management
New York
|
-$1.67M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$752K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$705K |
NUVB Hedge Fund Activity: Q4 2023 in Review
116 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q4 2023, worth a combined $203M — up 10% from $183M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of NUVB and 14 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 43 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $4.5M. The largest seller was Deep Track Capital, exiting entirely with an estimated $10.3M sold.
- 116 institutional investors held Nuvation Bio (NUVB) as of Q4 2023, down from 125 in Q3 2023.
- Funds reported $203M of Nuvation Bio stock for Q4 2023, up 10% quarter-over-quarter.
- 14 funds opened new Nuvation Bio positions in Q4 2023 and 23 closed out, a net change of -9 holders.
- The largest Nuvation Bio buyer in Q4 2023 was Tang Capital Management, an estimated $4.5M added.
- The largest Nuvation Bio seller in Q4 2023 was Deep Track Capital, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2023.